PE20160051A1 - Composicion que incluye atorvastatina o rosuvastatina, y acido acetilsalicilico - Google Patents

Composicion que incluye atorvastatina o rosuvastatina, y acido acetilsalicilico

Info

Publication number
PE20160051A1
PE20160051A1 PE2015002519A PE2015002519A PE20160051A1 PE 20160051 A1 PE20160051 A1 PE 20160051A1 PE 2015002519 A PE2015002519 A PE 2015002519A PE 2015002519 A PE2015002519 A PE 2015002519A PE 20160051 A1 PE20160051 A1 PE 20160051A1
Authority
PE
Peru
Prior art keywords
rosuvastatin
composition including
including atorvastatin
acetylsalicilic acid
acid
Prior art date
Application number
PE2015002519A
Other languages
English (en)
Inventor
Hurtado Javier Urbano
Sanz Pablo Martin
Original Assignee
Ferrer Int
Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii filed Critical Ferrer Int
Publication of PE20160051A1 publication Critical patent/PE20160051A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica que incluye un inhibidor de la HMG-CoA reductasa seleccionada de atorvastina y rosuvastatina y acido acetilsalicilico de manera que se minimiza la interaccion del acido acetilsalicilico con la estatina, para la prevencion o el tratamiento de enfermedades cardiovasculares
PE2015002519A 2013-06-06 2014-06-05 Composicion que incluye atorvastatina o rosuvastatina, y acido acetilsalicilico PE20160051A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
PE20160051A1 true PE20160051A1 (es) 2016-01-25

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002519A PE20160051A1 (es) 2013-06-06 2014-06-05 Composicion que incluye atorvastatina o rosuvastatina, y acido acetilsalicilico

Country Status (42)

Country Link
US (1) US10617699B2 (es)
EP (3) EP2810644A1 (es)
JP (1) JP6151854B2 (es)
KR (1) KR101839665B1 (es)
CN (2) CN113143888A (es)
AP (1) AP2015008882A0 (es)
AR (1) AR096350A1 (es)
AU (1) AU2014276883B2 (es)
BR (1) BR112015030350B1 (es)
CA (1) CA2912350C (es)
CL (1) CL2015003561A1 (es)
CR (1) CR20150635A (es)
CU (1) CU24326B1 (es)
CY (1) CY1118766T1 (es)
DK (1) DK2986281T3 (es)
DO (1) DOP2015000296A (es)
EA (1) EA028969B1 (es)
EC (1) ECSP15050273A (es)
ES (1) ES2620078T3 (es)
GE (1) GEP201706743B (es)
HK (1) HK1204562A1 (es)
HU (1) HUE033458T2 (es)
IL (1) IL242569B (es)
MA (1) MA38699B1 (es)
MD (1) MD4475C1 (es)
MX (1) MX347801B (es)
MY (1) MY181272A (es)
NI (1) NI201500171A (es)
NZ (1) NZ714707A (es)
PE (1) PE20160051A1 (es)
PH (1) PH12015502706A1 (es)
PL (1) PL2986281T3 (es)
PT (1) PT2986281T (es)
RS (1) RS55786B1 (es)
SA (1) SA515370243B1 (es)
SG (1) SG11201509353QA (es)
SI (1) SI2986281T1 (es)
TN (1) TN2015000501A1 (es)
TW (1) TWI630928B (es)
UA (1) UA113806C2 (es)
WO (1) WO2014195421A1 (es)
ZA (1) ZA201508452B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017021283A2 (pt) * 2015-04-16 2018-06-26 Novartis Ag comprimido de ribociclib
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
EP4299063B1 (en) 2022-06-30 2024-05-01 Ferrer Internacional, S.A. Oral capsules comprising atorvastatin tablets showing suitable dissolution profile and bioavailability

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
JP2000508659A (ja) 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
BRPI0108145B8 (pt) 2000-02-10 2021-05-25 Bpsi Holdings Inc composições de revestimento entérico acrílicas
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
CN1822820A (zh) * 2003-07-28 2006-08-23 雷迪实验室有限公司 心血管疾病的治疗和预防
JP4680061B2 (ja) 2003-08-20 2011-05-11 塩野義製薬株式会社 新規コーティング組成物
EP1689702B1 (en) 2003-11-26 2013-01-30 Novartis AG Organic compounds
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
CA2600674A1 (en) 2005-03-11 2006-09-14 Speedel Experimenta Ag Heterocyclic-substituted alkanamides useful as renin inhibitors
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
WO2009022821A2 (en) 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
KR20110007602A (ko) * 2008-03-28 2011-01-24 페레르 인터내쇼날 에스.에이. 심장혈관계 질병 예방용 캡슐
AU2010212580B2 (en) * 2009-02-11 2015-11-12 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
WO2011056126A1 (en) 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Novel 1,3-oxazolidine compounds and their use as renin inhibitors
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
CU20150173A7 (es) 2016-06-29
EP3175849A1 (en) 2017-06-07
AP2015008882A0 (en) 2015-11-30
HUE033458T2 (en) 2017-12-28
EP2810644A1 (en) 2014-12-10
CY1118766T1 (el) 2017-07-12
US10617699B2 (en) 2020-04-14
SG11201509353QA (en) 2015-12-30
BR112015030350B1 (pt) 2022-11-29
TWI630928B (zh) 2018-08-01
CL2015003561A1 (es) 2016-06-10
TN2015000501A1 (en) 2017-04-06
MX347801B (es) 2017-05-15
EP2986281A1 (en) 2016-02-24
RS55786B1 (sr) 2017-07-31
PT2986281T (pt) 2017-03-29
EA028969B1 (ru) 2018-01-31
MD20160001A2 (ro) 2016-05-31
MD4475B1 (ro) 2017-04-30
NI201500171A (es) 2019-05-07
ES2620078T3 (es) 2017-06-27
EA201600012A1 (ru) 2016-07-29
AU2014276883A1 (en) 2015-11-26
WO2014195421A1 (en) 2014-12-11
KR20160014622A (ko) 2016-02-11
ECSP15050273A (es) 2017-07-31
MX2015015753A (es) 2016-08-03
GEP201706743B (en) 2017-09-25
ZA201508452B (en) 2017-02-22
MY181272A (en) 2020-12-21
AU2014276883B2 (en) 2017-04-20
EP2986281B1 (en) 2016-12-21
PH12015502706B1 (en) 2016-03-14
US20160106763A1 (en) 2016-04-21
CA2912350C (en) 2017-04-04
PH12015502706A1 (en) 2016-03-14
AR096350A1 (es) 2015-12-23
IL242569B (en) 2018-12-31
SI2986281T1 (sl) 2017-07-31
JP2016520135A (ja) 2016-07-11
BR112015030350A2 (pt) 2017-07-25
CR20150635A (es) 2016-06-10
CU24326B1 (es) 2018-03-13
SA515370243B1 (ar) 2016-09-19
JP6151854B2 (ja) 2017-06-21
CN113143888A (zh) 2021-07-23
PL2986281T3 (pl) 2017-06-30
MA38699B1 (fr) 2017-09-29
CA2912350A1 (en) 2014-12-11
CN104224804A (zh) 2014-12-24
TW201536357A (zh) 2015-10-01
HK1204562A1 (en) 2015-11-27
UA113806C2 (xx) 2017-03-10
KR101839665B1 (ko) 2018-03-16
DK2986281T3 (en) 2017-04-03
DOP2015000296A (es) 2016-12-30
MD4475C1 (ro) 2017-11-30
NZ714707A (en) 2019-04-26
MA38699A1 (fr) 2017-01-31

Similar Documents

Publication Publication Date Title
PE20142182A1 (es) Inhibidores de iap
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
CR20130267A (es) Inhibidores de nampt y rock
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
PE20171042A1 (es) Inhibidores del bromodominio
EA201491817A1 (ru) Терапевтическое применение продуктов из косточек винограда шардоне
GT201400090A (es) 2-tiopirimidinonas
DOP2016000120A (es) Nuevos inhibidores de dgat2
CU24366B1 (es) Compuestos que poseen un anillo que contiene nitrógeno salicílico unido a un grupo heteroarilo bicíclico útiles como inhibidores rorc2
PE20160051A1 (es) Composicion que incluye atorvastatina o rosuvastatina, y acido acetilsalicilico
BR112015002275A2 (pt) processos e intermediários para a preparação de inibidores da integrase
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112013033836A2 (pt) terapia de combinação
CR20150124A (es) Formulación de una cápsula farmcéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
HRP20170263T1 (hr) LIJEČENJE ARTERIJSKE STJENKE KOMBINACIOJM RAAS INHIBITORA I HMG-CoA REDUKTAZE
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
SG11201801382UA (en) PHARMACEUTICAL COMPOSITION COMPRISING AN HMG-CoA REDUCTASE INHIBITOR AND AN ACE INHIBITOR
ES2524645B1 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CU20150043A7 (es) Inhibidores de la tirosina-quinasa de bruton
LV14963A (lv) Endoteliālās disfunkcijas korektors
TH1501001042A (th) สูตรผสมแคปซูลประกอบแต่งทางเภสัชกรรมที่ประกอบรวมด้วยเออร์เบซาร์แทน และตัวยับยั้ง hmg-coa รีดัคเทส